Advertisement

The tumor suppressor NDRG2 cooperates with an mTORC1 inhibitor to suppress the Warburg effect in renal cell carcinoma

  • Xi’an Li
  • Guangdong Hou
  • Zheng Zhu
  • Fei Yan
  • Fuli Wang
  • Di Wei
  • Yu Zheng
  • Jiarui Yuan
  • Wanxiang Zheng
  • Geng Zhang
  • Ping Meng
  • Yan Guo
  • Xia Li
  • Libo Yao
  • Lan ShenEmail author
  • Jianlin YuanEmail author
PRECLINICAL STUDIES

Summary

Renal cell carcinoma (RCC) is one of the most common malignancies worldwide, and metabolic reprogramming has a profound effect on RCC tumorigenesis. mTORC1 inhibitors are widely used in RCC treatment, yet some types of RCC cells are resistant to these compounds. Thus, clarification of the metabolic mechanism of mTORC1 inhibitors and exploration of new therapeutic approaches are urgently needed. In this study, we found that the mTORC1 pathway was hyperactive in RCC. Immunohistochemistry and western blot analysis showed that phosphorylation of the mTORC1 substrate 4EBP1 at threonine 37/46 increased in RCC tissues compared with that in normal renal tissues. It was also found that mTORC1 inhibitor everolimus suppressed glucose consumption, lactate production, and multiple catalytic enzymes involved in glycolysis in 786-O and ACHN cells, but the accumulation of HIF1α induced by CoCl2 blocked the inhibitory effect of everolimus on aerobic glycolysis. Interestingly, western blot and metabolite analysis showed that the tumor suppressor NDRG2 (N-Myc downstream regulated gene 2) was able to inhibit mTORC1 activity and cooperate with an mTOR inhibitor to decrease aerobic glycolysis in 786-O and ACHN cells. These results demonstrate that NDRG2 may potentially synergize with mTORC1 inhibitors to suppress malignant phenotype of RCC. Taken together, these data provided preclinical evidence that the combination of NDRG2 and mTORC1 inhibitors might be a promising strategy for RCC therapy.

Keywords

Warburg effect NDRG2 mTORC1 Everolimus Renal cell carcinoma 

Notes

Funding

This study was funded by grants from the National Natural Science Foundation of China (Nos. 81672542, 81872420, 81402572, 31700667 and 81230043), the Natural Science Foundation of Shaanxi Province (2017SF-187, 2017SF-102, 2016SF-162, 2014JM4184), the Key Science and Technology Program of Shaanxi Province (2014 K11–03–05-01), and the Military Medical Innovation Projects (16CXZ023).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interests.

Ethical approval

All experiments involved in this study were approved by both the Institutional Review Boards of The Fourth Military Medical University and the Ethics Committee of the above hospital.

Informed consent

Each patient provided a written consent prior to the study.

Supplementary material

10637_2019_839_MOESM1_ESM.pdf (461 kb)
ESM 1 (PDF 460 kb)

References

  1. 1.
    Linehan WM, Srinivasan R, Schmidt LS (2010) The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol 7(5):277–285.  https://doi.org/10.1038/nrurol.2010.47 CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Kaelin WG Jr (2007) The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin Cancer Res 13(2 Pt 2):680s–684s.  https://doi.org/10.1158/1078-0432.CCR-06-1865 CrossRefPubMedGoogle Scholar
  3. 3.
    Pal SK, Quinn DI (2013) Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat Rev 39(7):709–719.  https://doi.org/10.1016/j.ctrv.2012.12.015 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Cardillo TM, Trisal P, Arrojo R, Goldenberg DM, Chang CH (2013) Targeting both IGF-1R and mTOR synergistically inhibits growth of renal cell carcinoma in vitro. BMC Cancer 13:170.  https://doi.org/10.1186/1471-2407-13-170 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Deng Y, Yao L, Chau L, Ng SS, Peng Y, Liu X, Au WS, Wang J, Li F, Ji S, Han H, Nie X, Li Q, Kung HF, Leung SY, Lin MC (2003) N-Myc downstream-regulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation. Int J Cancer 106(3):342–347.  https://doi.org/10.1002/ijc.11228 CrossRefPubMedGoogle Scholar
  6. 6.
    Hu XL, Liu XP, Deng YC, Lin SX, Wu L, Zhang J, Wang LF, Wang XB, Li X, Shen L, Zhang YQ, Yao LB (2006) Expression analysis of the NDRG2 gene in mouse embryonic and adult tissues. Cell Tissue Res 325(1):67–76.  https://doi.org/10.1007/s00441-005-0137-5 CrossRefPubMedGoogle Scholar
  7. 7.
    Ma J, Jin H, Wang H, Yuan J, Bao T, Jiang X, Zhang W, Zhao H, Yao L (2008) Expression of NDRG2 in clear cell renal cell carcinoma. Biol Pharm Bull 31(7):1316–1320CrossRefPubMedGoogle Scholar
  8. 8.
    Liang ZL, Kang K, Yoon S, Huang SM, Lim JS, Kim JM, Lim JS, Lee HJ (2012) NDRG2 is involved in the oncogenic properties of renal cell carcinoma and its loss is a novel independent poor prognostic factor after nephrectomy. Ann Surg Oncol 19(8):2763–2772.  https://doi.org/10.1245/s10434-011-2204-3 CrossRefPubMedGoogle Scholar
  9. 9.
    Wu Z, Liao H, Su J, Yang L, Chi Z, OuYang X (2014) Adenovirus-mediated NDRG2 inhibits the proliferation of human renal cell carcinoma cell line OS-RC-2 in vitro. Cell Biochem Biophys 70(1):593–600.  https://doi.org/10.1007/s12013-014-9961-0 CrossRefPubMedGoogle Scholar
  10. 10.
    Ma JJ, Kong LM, Liao CG, Jiang X, Wang Y, Bao TY (2012) Suppression of MMP-9 activity by NDRG2 expression inhibits clear cell renal cell carcinoma invasion. Med Oncol 29(5):3306–3313.  https://doi.org/10.1007/s12032-012-0265-1 CrossRefPubMedGoogle Scholar
  11. 11.
    Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674.  https://doi.org/10.1016/j.cell.2011.02.013 CrossRefPubMedGoogle Scholar
  12. 12.
    Xu X, Li J, Sun X, Guo Y, Chu D, Wei L, Li X, Yang G, Liu X, Yao L, Zhang J, Shen L (2015) Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression. Oncotarget 6(28):26161–26176.  https://doi.org/10.18632/oncotarget.4544 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Pan T, Zhang M, Zhang F, Yan G, Ru Y, Wang Q, Zhang Y, Wei X, Xu X, Shen L, Zhang J, Wu K, Yao L, Li X (2017) NDRG2 overexpression suppresses hepatoma cells survival during metabolic stress through disturbing the activation of fatty acid oxidation. Biochem Biophys Res Commun 483(2):860–866.  https://doi.org/10.1016/j.bbrc.2017.01.018 CrossRefPubMedGoogle Scholar
  14. 14.
    Roulin D, Waselle L, Dormond-Meuwly A, Dufour M, Demartines N, Dormond O (2011) Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib. Mol Cancer 10:90.  https://doi.org/10.1186/1476-4598-10-90 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Wellik LE, Witzig TE, Rajkumar SV, Adjei AA, Kumar S (2010) Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene 29(8):1190–1202.  https://doi.org/10.1038/onc.2009.403 CrossRefPubMedGoogle Scholar
  16. 16.
    Karoulia Z, Gavathiotis E, Poulikakos PI (2017) New perspectives for targeting RAF kinase in human cancer. Nat Rev Cancer 17(11):676–691.  https://doi.org/10.1038/nrc.2017.79 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    De Mulder PH (2007) Targeted therapy in metastatic renal cell carcinoma. Ann Oncol 18(Suppl 9):ix98–ix102.  https://doi.org/10.1093/annonc/mdm303 CrossRefPubMedGoogle Scholar
  18. 18.
    Barthelemy P, Hoch B, Chevreau C, Joly F, Laguerre B, Lokiec F, Duclos B (2013) mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice. Crit Rev Oncol Hematol 88(1):42–56.  https://doi.org/10.1016/j.critrevonc.2013.02.006 CrossRefPubMedGoogle Scholar
  19. 19.
    Nakahata S, Ichikawa T, Maneesaay P, Saito Y, Nagai K, Tamura T, Manachai N, Yamakawa N, Hamasaki M, Kitabayashi I, Arai Y, Kanai Y, Taki T, Abe T, Kiyonari H, Shimoda K, Ohshima K, Horii A, Shima H, Taniwaki M, Yamaguchi R, Morishita K (2014) Loss of NDRG2 expression activates PI3K-AKT signalling via PTEN phosphorylation in ATLL and other cancers. Nat Commun 5:3393.  https://doi.org/10.1038/ncomms4393 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Hardie DG (2014) AMPK--sensing energy while talking to other signaling pathways. Cell Metab 20(6):939–952.  https://doi.org/10.1016/j.cmet.2014.09.013 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Semenza GL (2010) HIF-1: upstream and downstream of cancer metabolism. Curr Opin Genet Dev 20(1):51–56.  https://doi.org/10.1016/j.gde.2009.10.009 CrossRefPubMedGoogle Scholar
  22. 22.
    Aoki M, Fujishita T (2017) Oncogenic roles of the PI3K/AKT/mTOR Axis. Curr Top Microbiol Immunol 407:153–189.  https://doi.org/10.1007/82_2017_6 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Urology, Xijing HospitalFourth Military Medical UniversityXi’anChina
  2. 2.Department of Biochemistry and Molecular BiologyFourth Military Medical UniversityXi’anChina
  3. 3.Department of Gene TechnologyFourth Military Medical UniversityXi’anChina
  4. 4.School of MedicineSt. George’s UniversityWest IndiesGrenada

Personalised recommendations